0000950170-24-021575.txt : 20240227
0000950170-24-021575.hdr.sgml : 20240227
20240227200020
ACCESSION NUMBER: 0000950170-24-021575
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240223
FILED AS OF DATE: 20240227
DATE AS OF CHANGE: 20240227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Halstead Michael
CENTRAL INDEX KEY: 0001521548
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 24689517
MAIL ADDRESS:
STREET 1: C/O WARNER CHILCOTT CORPORATION
STREET 2: 100 ENTERPRISE DRIVE
CITY: ROCKAWAY
STATE: NJ
ZIP: 07866
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
ownership.xml
4
X0508
4
2024-02-23
false
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001521548
Halstead Michael
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
false
true
false
false
EVP and General Counsel
true
Common Stock
2024-02-23
4
M
false
7907
A
7907
D
Common Stock
2024-02-26
4
S
false
300
68.54
D
7607
D
Common Stock
2024-02-26
4
S
false
7215
69.54
D
392
D
Common Stock
2024-02-26
4
S
false
392
70.13
D
0
D
Restricted Stock Units
2024-02-23
4
M
false
7907
0
D
Common Stock
7907
0
D
Restricted stock units convert into common stock on a one-for-one basis.
This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 15, 2023 and amended on May 8, 2023 and August 11, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.02 to $68.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.205 to $70.0175, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.02 to $70.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
/s/ Lawrence J. Hineline, Attorney-in-fact
2024-02-27